56 related articles for article (PubMed ID: 14737089)
41. Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.
Galili U
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933166
[TBL] [Abstract][Full Text] [Related]
42. Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Taniyama K; Kamiike W; Mori M; Doki Y
Cancer Sci; 2013 Mar; 104(3):282-90. PubMed ID: 23240661
[TBL] [Abstract][Full Text] [Related]
43. [The alpha-gal epitope (Gal alpha 1-3 Gal beta 1-4 GlcNAc-R) in xenotransplantation].
Peng SY; Wang WJ
Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):248-50. PubMed ID: 14628474
[No Abstract] [Full Text] [Related]
44. Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Galili U; Chen ZC; Manches O; Plumas J; Preisler H
J Hematother Stem Cell Res; 2001 Aug; 10(4):501-11. PubMed ID: 11522233
[TBL] [Abstract][Full Text] [Related]
45. Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections.
Galili U
Antibodies (Basel); 2020 Jun; 9(2):. PubMed ID: 32580274
[TBL] [Abstract][Full Text] [Related]
46. Paleo-immunology of human anti-carbohydrate antibodies preventing primate extinctions.
Galili U
Immunology; 2023 Jan; 168(1):18-29. PubMed ID: 36161654
[TBL] [Abstract][Full Text] [Related]
47. α-Gal Nanoparticles in Wound and Burn Healing Acceleration.
Galili U
Adv Wound Care (New Rochelle); 2017 Mar; 6(3):81-92. PubMed ID: 28289553
[No Abstract] [Full Text] [Related]
48. Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope.
Galili U
Subcell Biochem; 1999; 32():1-23. PubMed ID: 10391989
[No Abstract] [Full Text] [Related]
49. In the beginning: induction of prenatal tolerance still an elusive goal.
High K
Mol Ther; 2000 Oct; 2(4):300-1. PubMed ID: 11020344
[No Abstract] [Full Text] [Related]
50. Accelerated Burn Healing in a Mouse Experimental Model Using α-Gal Nanoparticles.
Galili U
Bioengineering (Basel); 2023 Oct; 10(10):. PubMed ID: 37892895
[TBL] [Abstract][Full Text] [Related]
51. Generation of alpha 1,3galactosyltransferase deficient mice.
Thall AD
Subcell Biochem; 1999; 32():259-79. PubMed ID: 10391999
[No Abstract] [Full Text] [Related]
52. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene.
Ogawa H; Yin DP; Galili U
Gene Ther; 2004 Feb; 11(3):292-301. PubMed ID: 14737089
[TBL] [Abstract][Full Text] [Related]
53. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
54. Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies.
Galili U
Front Mol Biosci; 2023; 10():1209974. PubMed ID: 37449060
[TBL] [Abstract][Full Text] [Related]
55. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
Galili U
Immunol Cell Biol; 2005 Dec; 83(6):674-86. PubMed ID: 16266320
[TBL] [Abstract][Full Text] [Related]
56. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens.
Galili U
Transplantation; 2004 Oct; 78(8):1093-8. PubMed ID: 15502700
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
